Those are class-relevant issues across GLP-1 and incretin-based drugs
Nocito MC, Hantel C, Lerario AM, Mastrorocco F, De Martino L, Musicco C, et al
It functions as a dual GLP-1 and GIP receptor agonist , offering: Enhanced insulin secretion Delayed gastric emptying Appetite suppression Improved glycemic control Tirzepatide demonstrated impressive clinical outcomes in the SURMOUNT and SURPASS trials, with average weight loss of 15-22.5% and substantial A1C reductions
Remote consultation telehealth platforms have increased access to care because patients can now communicate with licensed clinicians without the need to travel to physical locations
Tsai YL, Lin TL, Chang CJ, Tsung-Ru W, Lai WF, Chia-Chen L, Lai HC
Dysfunction in these pathways can trigger neurodegeneration and motor dysfunction